Genetic and neuroscience advances are providing ideas for biology-based interventions in autism spectrum disorder, but none of these have translated to new treatments. Dr. Veenstra-VanderWeele will discuss opportunities and challenges for the pathway from bench to bedside. He will highlight the power and limitations of model systems, as well as the uncertainty around target populations and clinical outcome measures.
